2Q26 EPS: Fundamentals Take the Baton — Style Leadership Emerging Across SMID-Cap Biotech

Research evidence excerpt

2Q26 EPS: Fundamentals Take the Baton — Style Leadership Emerging Across SMID-Cap Biotech

Idea

Neurocrine Biosciences IncMcharacteristics more commonly associated with high-quality growth businesses:

(NBIX.O) From To

durable demand, expanding operating leverage, increasing self-funding capability, Price Target $191.00 $193.00

and meaningful optionality from pipeline expansion. Within this cohort, ARGX, ONC, PTC Therapeutics (PTCT.O) From To

INSM, IONS, PTCT, and ASND stand out as differentiated franchises where earnings Price Target $94.00 $93.00

should increasingly highlight revenue durability and improving visibility into 2026–

27 growth trajectories. We believe investors remain willing to reward execution and

predictability, particularly as biotech valuations remain reasonable relative to

broader growth sectors.

The Compounders' Club - ARGX, ONC, INSM, IONS, PTCT, and ASND continue to

distinguish themselves through strong execution, multiple growth drivers, and

increasing earnings visibility. Within commercial-stage biotech, style preference

remains tilted toward companies capable of combining growth with improving

profitability. ARGX continues to evolve beyond a single-product story as multiple

autoimmune catalysts approach. ONC offers a differentiated commercial oncology

platform with growing strategic value, while INSM remains one of the strongest

execution stories in biotech as physician adoption and market expansion continue.

IONS and PTCT represent examples where launch execution and operating leverage

may increasingly drive estimate revisions, while RARE offers attractive duration

through its expanding rare disease portfolio. These companies collectively share a

common characteristic: multiple avenues to compound value independent of

broader sector sentiment.